Please assess the completion status of the following clinical trial:

Trial Title: Bronx MBCT-Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ICHD-3 beta headache diagnosis of migraine,~* self-reported and diary-confirmed 4-20 headache days per month~* aged 18-65~* ability to read English~* capacity to consent.~Exclusion Criteria:~* no ICHD-3 beta headache diagnosis of migraine~* fewer than 4 or greater than 20 headache days per month~* under 18 or over 65~* inability to read English~* lacking the capacity to consent~* utilization of new preventative pain treatments within four weeks of the baseline assessment, or a plan to utilize new preventive pain medications during the duration of the study~* severe psychiatric illness that would interfere with participation in the treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- MBCT for Migraine (Type: EXPERIMENTAL): In this arm, participants will receive 8 weeks of the manualized treatment Mindfulness Based Cognitive Therapy (MBCT; Day \& Thorn). Participants will attend weekly 75-90 minute individual sessions for eight weeks. At each weekly session one of eight broad topics are addressed and discussed (Automatic-Pilot, Dealing with Barriers, Mindfulness of Breath, Staying Present, Allowing/Letting Be, Cognitive Restructuring, Self Care, Application to Headache Pain). Homework is assigned each week, and participants are expected to develop a daily formal mindfulness practice (body scan meditation, seated meditation, breathing meditation, etc). Participants are provided with a course manual, reading materials, and audio recordings to facilitate meditation practice.
- Wait List/Treatment as Usual (Type: NO_INTERVENTION): Patients will continue with standard care. Patients will be offered MBCT after the primary endpoint.

Based on this trial design, predict the completion outcome and termination type (if applicable).